XML 128 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets (Tables)
12 Months Ended
Dec. 31, 2019
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Schedule of Indefinite-Lived Intangible Assets
The following table summarizes our intangible assets, net (in millions):
 
 
December 31, 2019
 
December 31, 2018
 
 
Gross 
Carrying
Amount
 
Accumulated
Amortization
 
Foreign Currency Translation Adjustment
 
Net Carrying Amount
 
Gross 
Carrying
Amount
 
Accumulated
Amortization
 
Foreign Currency Translation Adjustment
 
Net Carrying Amount
Finite-lived assets
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intangible asset - sofosbuvir
 
$
10,720

 
$
(4,253
)
 
$

 
$
6,467

 
$
10,720

 
$
(3,554
)
 
$

 
$
7,166

Intangible asset - axicabtagene ciloleucel (DLBCL)
 
6,200

 
(761
)
 

 
5,439

 
6,200

 
(416
)
 

 
5,784

Intangible asset - Ranexa
 
688

 
(688
)
 

 

 
688

 
(678
)
 

 
10

Other
 
1,098

 
(454
)
 
(6
)
 
638

 
1,096

 
(359
)
 
(3
)
 
734

Total finite-lived assets
 
18,706

 
(6,156
)
 
(6
)
 
12,544

 
18,704

 
(5,007
)
 
(3
)
 
13,694

Indefinite-lived assets - IPR&D
 
1,247

 

 
(5
)
 
1,242

 
2,047

 

 
(3
)
 
2,044

Total intangible assets
 
$
19,953

 
$
(6,156
)
 
$
(11
)
 
$
13,786

 
$
20,751

 
$
(5,007
)
 
$
(6
)
 
$
15,738


Schedule of Finite-Lived Intangible Assets
The following table summarizes our intangible assets, net (in millions):
 
 
December 31, 2019
 
December 31, 2018
 
 
Gross 
Carrying
Amount
 
Accumulated
Amortization
 
Foreign Currency Translation Adjustment
 
Net Carrying Amount
 
Gross 
Carrying
Amount
 
Accumulated
Amortization
 
Foreign Currency Translation Adjustment
 
Net Carrying Amount
Finite-lived assets
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intangible asset - sofosbuvir
 
$
10,720

 
$
(4,253
)
 
$

 
$
6,467

 
$
10,720

 
$
(3,554
)
 
$

 
$
7,166

Intangible asset - axicabtagene ciloleucel (DLBCL)
 
6,200

 
(761
)
 

 
5,439

 
6,200

 
(416
)
 

 
5,784

Intangible asset - Ranexa
 
688

 
(688
)
 

 

 
688

 
(678
)
 

 
10

Other
 
1,098

 
(454
)
 
(6
)
 
638

 
1,096

 
(359
)
 
(3
)
 
734

Total finite-lived assets
 
18,706

 
(6,156
)
 
(6
)
 
12,544

 
18,704

 
(5,007
)
 
(3
)
 
13,694

Indefinite-lived assets - IPR&D
 
1,247

 

 
(5
)
 
1,242

 
2,047

 

 
(3
)
 
2,044

Total intangible assets
 
$
19,953

 
$
(6,156
)
 
$
(11
)
 
$
13,786

 
$
20,751

 
$
(5,007
)
 
$
(6
)
 
$
15,738


Schedule of Estimated Future Amortization Expense
Fiscal Year
Amount
2020
$
1,125

2021
1,124

2022
1,124

2023
1,124

2024
1,125

Thereafter
6,922

Total
$
12,544